Vif and Apobec3G in the innate immune response to HIV: A tale of two proteins

Future Microbiology

Volumn 3, Issue 2, 2008, Pages 145-154

  Farrow, Melissa A ^a   Sheehy, Ann M ^a  

^a Department of Biology   (United States)

Author keywords

Apbec3G; Deamination; Proteasomal degradation; Reverse transcription; Ribonucleoprotein complexes; RNA metabolism; Vif

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD4 ANTIGEN; MESSENGER RNA; TRANSCRIPTION FACTOR; VIF PROTEIN; VIRUS DNA;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; DRUG BINDING SITE; DRUG TARGETING; EPIDEMIC; GENETIC REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; LIFE CYCLE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; VIRION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

CYTIDINE DEAMINASE; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, NATURAL; MODELS, BIOLOGICAL; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 47249103367     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.2.145     Document Type: Review

References (80)

1. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA: The HIV'A' (sor) gene product is essential for virus infectivity. Nature 328, 728-730 (1987).
2. Fisher AG, Ensoli B, Ivanoff L et al.: The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237, 888-893 (1987).
3. + T lymphocytes. J. Virol. 66, 6489-6495 (1992).
4. von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67, 4945-4955 (1993).
5. Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72, 10251-10255 (1998).
6. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4, 1397-1400 (1998).
7. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
8. Cullen BR: Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80, 1067-1076 (2006).
9. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112 (2003).
10. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (2003).
11. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98 (2003).
12. Harris RS, Bishop KN, Sheehy AM et al.: DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809 (2003).
13. Yu Q, Konig R, Pillai S et al.: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11, 435-442 (2004).
14. Jarmuz A, Chester A, Bayliss J et al.: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296 (2002).
15. Di Noia JM, Neuberger MS: Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 76, 1-22 (2007).
16. Wedekind JE, Dance GS, Sowden MP, Smith HC: Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19, 207-216 (2003).
17. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279, 53379-53386 (2004).
18. Chen H, Lilley CE, Yu Q et al.: APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16, 480-485 (2006).
19. OhAinle M, Kerns JA, Malik HS, Emerman M: Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80, 3853-3862 (2006).
20. Okazaki IM, Hiai H, Kakazu N et al.: Constitutive expression of AID leads to tumorigenests. J. Exp. Med. 197, 1173-1181 (2003).
21. Chiu YL, Greene WC: APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. J. Biol. Chem. 281, 8309-8312 (2006).
22. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S: Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 34, 4677-4684 (2006).
23. Yang B, Chen K, Zhang C, Huang S, Zhang H: Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282, 11667-11675 (2007).
24. Mbisa JL, Barr R, Thomas JA et al.: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81, 7099-7110 (2007).
25. Luo K, Wang T, Liu B et al.: Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81, 7238-7248 (2007).
26. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14, 1392-1396 (2004).
27. Liddament MT, Brown WL, Schumacher AJ, Harris RS: APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in wvo. Curr. Biol. 14, 1385-1391 (2004).
28. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J. 23, 2451-2458 (2004).
29. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78, 6073-6076 (2004).
30. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS: Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337, 585-596 (2004).
31. Dang Y, Wang X, Esselman WJ, Zheng YH: Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80, 10522-10533 (2006).
32. Stenglein MD, Harris RS: APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281, 16837-16841 (2006).
33. Newman EN, Holmes RK, Craig HM et al.: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166-170 (2005).
34. Bishop KN, Holmes RK, Malim MH: Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80, 8450-8458 (2006).
35. Holmes RK, Koning FA, Bishop KN, Malim MH: APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282, 2587-2595 (2007).
36. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L: Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80, 11710-11722 (2006).
37. Guo F, Cen S, Niu M, Yang Y, Gorelick RJ, Kleiman L: The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81, 11322-11331 (2007).
38. Li XY, Guo F, Zhang L, Kleiman L, Cen S: APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282(44), 32065-32074 (2007).
39. Holmes RK, Malim MH, Bishop KN: APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32, 118-128 (2007).
40. + T cells. Nature 435, 108-114 (2005).
41. Thielen BK, Klein KC, Walker LW et al.: T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity. PLoS Pathog. 3, e135 (2007).
42. Miyagi E, Opi S, Takeuchi H et al.: Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81, 13346-13353 (2007).
43. Schumacher AJ, Hache G, Macduff DA, Brown WL, Harris RS: The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD and HIV-1 restriction. J. Virol. 82(6), 2652-2660 (2008).
44. Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13, 2009-2013 (2003).
45. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9, 1398-1403 (2003).
46. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-147 (2003).
47. Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 12, 591-601 (2003).
48. Yu X, Yu Y, Liu B et al.: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cu15-SCF complex. Science 302, 1056-1060 (2003).
49. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279, 7792-7798 (2004).
50. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF: Selective assembly of HIV-1 Vif-Cu15-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18, 2867-2872 (2004).
51. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cu15 complex that promotes APOBEC3G degradation. Genes Dev. 18, 2861-2866 (2004).
52. Opi S, Kao S, Goila-Gaur R et al.: Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81, 8236-8246 (2007).
53. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L: The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279, 33177-33184 (2004).
54. Luo K, Liu B, Xiao Z et al.: Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78, 11841-11852 (2004).
55. Svarovskaia ES, Xu H, Mbisa JL et al.: Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279, 35822-35828 (2004).
56. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD: APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78, 12058-12061 (2004).
57. Huthoff H, Malim MH: Identification of amino acid residues in APOBEC3G required for regulation by HIV-1 Vif and virion encapsidation. J. Virol. 81, 3807-3815 (2007).
58. Overbaugh J, Bangham CR: Selection forces and constraints on retroviral sequence variation. Science 292, 1106-1109 (2001).
59. Hache G, Mansky LM, Harris RS: Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 8, 148-157 (2006).
60. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD: Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1, e6 (2005).
61. Muckenfuss H, Kaiser JK, Krebil E et al.: Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res. 35, 3784-3796 (2007).
62. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM: Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203, 41-46 (2006).
63. Rose KM, Marin M, Kozak SL, Kabat D: Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J. Biol. Chem. 279, 41744-41749 (2004).
64. Kreisberg JF, Yonemoto W, Greene WC: Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203, 865-870 (2006).
65. Tanaka Y, Marusawa H, Seno H et al.: Anti-viral protein APOBEC3G is induced by interferon-α stimulation in human hepatocytes. Biochem. Biophys. Res. Commun. 341, 314-319 (2006).
66. Jin X, Brooks A, Chen H, Bennett R, Reichman R, Smith H: APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J. Virol. 79, 11513-11516 (2005).
67. Jin X, Wu H, Smith H: APOBEC3G levels predict rates of progression to AIDS. Retrovirology 4, 20 (2007).
68. Biasin M, Piacentini L, Caputo SL et al.: Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J. Infect. Dis. 195, 960-964 (2007).
69. Gallois-Montbrun S, Kramer B, Swanson CM et al.: Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81, 2165-2178 (2007).
70. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D: The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281, 29105-29119 (2006).
71. Wichroski MJ, Robb GB, Rana TM: Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies, PLoS Pathog. 2, e41 (2006).
72. Huang J, Liang Z, Yang B, Tian H, Ma J, Zhang H: Derepression of micro-RNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members. J. Biol. Chem. 282(46), 33632-33640 (2007).
73. Chiu YL, Witkowska HE, Hall SC et al.: High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl Acad. Sci. USA 103, 15588-15593 (2006).
74. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC: Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282, 3539-3546 (2007).
75. + monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178, 6581-6589 (2007).
76. Peng G, Greenwell-Wild T, Nares S et al.: Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110, 393-400 (2007).
77. Soros VB, Yonemoto W, Greene WC: Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3, e15 (2007).
78. Mehle A, Wilson H, Zhang C et al.: Identification of an APOBEC3G binding site in HIV-1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81, 13235-13241 (2007).
79. Russell RA, Pathak VK: Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201-8210 (2007).
80. Zhang L, Saadatmand J, Li X et al.: Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370, 113-121 (2008).